We have designed a highly sensitive assay based on the Safe-SeqS technology to detect de novo mutations in the KIT gene and tested its performance. This assay was applied to plasma samples of GIST patients before and after treatment with regorafenib (GRID III trial) and mutations at known and novel sites of potential secondary resistance were identified.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-3-319-42044-8_34 | DOI Listing |
Publication Analysis
Top Keywords
detection quantification
4
quantification kit
4
kit mutations
4
mutations ctdna
4
ctdna plasma
4
plasma safe-seqs
4
safe-seqs designed
4
designed highly
4
highly sensitive
4
sensitive assay
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!